

"Express Mail" mailing number: ET475301827US  
Date of Deposit October 25, 2001  
I hereby certify that this paper and all papers and fees referred to herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents, Washington, D.C.  
Shaylor E. Dunn



RECEIVED

JAN 17 2002

TECH CENTER 1600/2900

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Daniel et al.

Group Art Unit: 1623

**Serial No.: 09/516,728**

Examiner: Bansal, G.

Filed: March 1, 2000

Docket No.: 1242/12/2 CIP

Confirmation No.: 2723

For: MODULATION OF ENDOTHELIAL CELL SURFACE RECEPTOR ACTIVITY IN THE REGULATION OF ANGIOGENESIS

\*\*\*\*\*

**STATEMENT THAT SEQUENCE LISTING AND COMPUTER READABLE COPY ARE THE SAME**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.821(f), applicants hereby state that the Sequence Listing information recorded in computer readable form is identical to the written Sequence Listing on paper.


Although a check is being submitted, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number **50-0426**.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 10/25/01

By:

  
Arles A. Taylor, Jr.  
Registration No. 39,395

Suite 1400 University Tower  
3100 Tower Boulevard  
Durham, North Carolina 27707  
Telephone: (919) 493-8000  
Facsimile: (919) 419-0383

Customer No. Bar Code Label: 

1242/12/2 AAT/ajm

25297

PATENT TRADEMARK OFFICE

BEST AVAILABLE COPY

no written description for analog or derivative  
Fragment is less than the full length

**BEST AVAILABLE COPY**

09/516728 March 12000.

(600)  
PASTV

C-I-P. of 09/152,160 September 10, 1998. 6248327 patent X

No. prelin Andt

I

Antibody to DEP-1/ECRTP.  
Claims 1 - 14.

II

A pharmaceutical comp<sup>any</sup> company ECRTP/DEP-1 peptide or chemist  
15-18 derivatives thereof, kit containing peptide  
38-44.  
a method of screening for a substance that modulates  
c-jun kinase.

III

Claims 19-25 method involves ligand isolated by lymphocytes, different  
28-30, 37 passing.

IV

Same method as above

Claim 26 method involves recombinant method of making the ligand

V

Recombinant cell for use in assay of claim 2

Claim 27

VI

BEST AVAILABLE COPY

Priority 152160  
March 12000  
09/516728 Electron  
Sep 10, 1998

NC Traverse Electron Claims 1-14

drawn to antibody.

an antibody preferentially binds to <sup>ectodomain</sup> ECRTP/DEP-1 or fragments or derivative of the Ab.

Need Seq in claims.

2

Claim 1 is drawn to an antibody which preferentially binds to ECRTP/DEP-1

WO 9730002 teaches an antibody to a DEP1 polypeptide of Seq ID#2 human DEP-1  
Also teaches a Type III density enhanced protein tyrosine phosphatase ~~enzymatic~~

general Ab

1 14

4

~~14~~

2, 3, 5, 6, 7, 9

10, 11, 12, 13

1, 4, 8, 14 > 102(b) 3a claims 23 27

1, 4 fragment.  
What's a derivative?

2, 35 preferentially

immuno reaction characteristics

**BEST AVAILABLE COPY**  
**COPY**



Application No.: 09/516728

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: *If Applicable* Applicant should follow the format of the attached sample statement to request that the CRF filed in the parent application be used to create a CRF in this application.

**Applicant Must Provide:**

An Initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An Initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

TECH CENTER 1600/2900

JAN 17 2002

RECEIVED